Individual Study / LIPID study

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study:

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study:

Initiatives -
LIPID study was designed to examine the effects of 40mg pravastatin o.d on cardiovascular outcomes in patients who were stable after myocardial infarction or hospitalisation for unstable angina 3-36 months previously. *Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study.*
Start Year
1990
End Year
1997
Funding
NHMRC Clinical Trials Centre, University of Sydney, under the auspices of the National Heart Foundation of Australia.

Members

Download
Investigators Contacts
  • Dr. Peter J. Meikle
    Baker Heart and Diabetes Institute
  • Dr. Prof. Anne Tonkin
    University of Adelaide · School of Medicine

Design

Study design
Clinical trial cohort
Follow Up
A mean follow-up of 6 years

Marker Paper

LIPID Study Group. (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. The Lancet, 359(9315), 1379-1387.

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
9,014
Number of participants with biosamples
Supplementary Information
Patients were recruited from 87 centres in Australia and New Zealand. Aged 31-75 years.

Access

Availability of data and biosamples

Data
Biosamples
Other